Last reviewed · How we verify
Malaria Vaccine 257049
Malaria Vaccine 257049 is a Recombinant protein vaccine Biologic drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Malaria prevention in endemic populations, particularly children and infants.
This vaccine stimulates the immune system to recognize and attack Plasmodium parasites that cause malaria by targeting the parasite's pre-erythrocytic and blood-stage antigens.
This vaccine stimulates the immune system to recognize and attack Plasmodium parasites that cause malaria by targeting the parasite's pre-erythrocytic and blood-stage antigens. Used for Malaria prevention in endemic populations, particularly children and infants.
At a glance
| Generic name | Malaria Vaccine 257049 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Recombinant protein vaccine |
| Target | Plasmodium falciparum circumsporozoite protein (CSP) and/or blood-stage antigens |
| Modality | Biologic |
| Therapeutic area | Infectious Disease / Immunology |
| Phase | Phase 3 |
Mechanism of action
Malaria Vaccine 257049 (likely RTS,S/Mosquirix or a related candidate) uses recombinant protein technology to present malaria parasite antigens to the immune system, triggering both cellular and humoral immune responses. The vaccine is designed to prevent parasites from infecting hepatocytes and/or reduce parasitemia levels, thereby preventing clinical malaria disease.
Approved indications
- Malaria prevention in endemic populations, particularly children and infants
Common side effects
- Injection site pain or swelling
- Fever
- Fatigue
- Myalgia
Key clinical trials
- Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants (PHASE2)
- A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Candidate Vaccines RTS,S/AS02D (0.5 mL Dose) and RTS,S/AS02A (0.25 mL Dose) Administered IM According to a 0, 1, 2 Month Vaccination Schedule in Children Aged 3 to 5 Years Living in a Malaria-endemic Region of Mozambique. (PHASE1)
- An Extension to Study MALARIA-055 PRI (NCT00866619) to Evaluate the Long-term Efficacy, Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine in Infants and Children in Africa (PHASE3)
- Efficacy of GSK Biologicals' Candidate Malaria Vaccine 257049 Against Malaria Disease in Infants and Children in Africa (PHASE3)
- Study to Evaluate Immunogenicity of the Hepatitis B Antigen of the GSK Biologicals' Candidate Malaria Vaccine (257049) (PHASE3)
- Efficacy, Safety and Immunogenicity Study of GlaxoSmithKline(GSK) Biologicals' Candidate Malaria Vaccine 257049 in the Sporozoite Challenge Model in Healthy Malaria-naïve Adults (PHASE2)
- Safety, Immunogenicity and Efficacy Against of a Combined Malaria Vaccine in Healthy Malaria-naïve Adults (PHASE2)
- Safety and Immunogenicity of GSK Biologicals' Investigational Malaria Vaccine in HIV Infected Infants and Children (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Malaria Vaccine 257049 CI brief — competitive landscape report
- Malaria Vaccine 257049 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Malaria Vaccine 257049
What is Malaria Vaccine 257049?
How does Malaria Vaccine 257049 work?
What is Malaria Vaccine 257049 used for?
Who makes Malaria Vaccine 257049?
What drug class is Malaria Vaccine 257049 in?
What development phase is Malaria Vaccine 257049 in?
What are the side effects of Malaria Vaccine 257049?
What does Malaria Vaccine 257049 target?
Related
- Drug class: All Recombinant protein vaccine drugs
- Target: All drugs targeting Plasmodium falciparum circumsporozoite protein (CSP) and/or blood-stage antigens
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Immunology
- Indication: Drugs for Malaria prevention in endemic populations, particularly children and infants
- Compare: Malaria Vaccine 257049 vs similar drugs
- Pricing: Malaria Vaccine 257049 cost, discount & access